+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Anti-N-methyl-d-aspartate receptor encephalitis in a patient with neuromyelitis optica spectrum disorders



Anti-N-methyl-d-aspartate receptor encephalitis in a patient with neuromyelitis optica spectrum disorders



Multiple Sclerosis and Related Disorders 8: 74-77



We described a female patient with anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis occurring sequentially with neuromyelitis optica spectrum disorders (NMOSD). The 19-year-old patient initially presented a diencephalic syndrome with aquaporin-4 immunoglobulin G antibodies (AQP4-IgG) and brain lesions which involving bilateral medial temporal lobes and periependymal surfaces of the third ventricle on magnetic resonance imaging (MRI). Ten months later, the patient developed cognitive impairment, psychiatric symptoms and dyskinesia with left basal ganglia lesions on brain MRI. Meanwhile, the anti-NMDAR antibodies were positive in the patient's serum and cerebrospinal fluid, while the screening tests for an ovarian teratoma and other tumors were all negative. Hence, the patient was diagnosed NMOSD and anti-NMDAR encephalitis followed by low-dose rituximab treatment with a good response. This case was another evidence for demyelinating syndromes overlapping anti-NMDAR encephalitis in Chinese patients.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057206163

Download citation: RISBibTeXText

PMID: 27456878

DOI: 10.1016/j.msard.2016.05.002


Related references

Anti-N-methyl-D-aspartate receptor(NMDAR) antibody encephalitis presents in atypical types and coexists with neuromyelitis optica spectrum disorder or neurosyphilis. Bmc Neurology 17(1): 1, 2017

Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis. Multiple Sclerosis and Related Disorders 20: 144-152, 2018

Deterioration of clinical features of a patient with autism spectrum disorder after anti-N-methyl-D-aspartate receptor encephalitis. Psychiatry and Clinical Neurosciences 69(8): 507, 2016

Neuromyelitis optica and neuromyelitis optica spectrum disorders: the evaluation of 86 patients followed by Istanbul Bilim University, Department of Neurology. Journal of the Neurological Sciences 357: E296-E297, 2015

Circulating Memory T Follicular Helper Cells in Patients with Neuromyelitis Optica/Neuromyelitis Optica Spectrum Disorders. Mediators of Inflammation 2016: 3678152, 2017

Clinical characteristics and follow-up of pediatric patients with neuromyelitis optica and neuromyelitis optica spectrum disorders. Zhonghua Er Ke Za Zhi 53(4): 268-273, 2016

Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic Populations. Aaps Journal 21(3): 42, 2019

Neuromyelitis optica and neuromyelitis optica like spectrum disorders: Is it not the time to change the criteria?. Multiple Sclerosis and Related Disorders 20: 153, 2018

Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate. Bmc Neurology 14: 51, 2014

A case of anti-N-methyl-D-aspartate receptor encephalitis with ovarian teratoma showing excellent recovery with decreasing of anti-N-methyl-D-aspartate receptor antibody. Rinsho Shinkeigaku 51(7): 499-504, 2011

Anti-C1q autoantibodies in patients with neuromyelitis optica spectrum disorders. Journal of Neuroimmunology 310: 150-157, 2017

Anti-MOG + neuromyelitis optica spectrum disorders treated with plasmapheresis. No to Hattatsu 48(3): 199-203, 2016

Anti-NMDAR encephalitis followed by seropositive neuromyelitis optica spectrum disorder: A case report and literature review. Clinical Neurology and Neurosurgery 155: 75-82, 2017

Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up. Journal of the Neurological Sciences 372: 92-96, 2017

Peripheral CD19 + B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders. Journal of Neurology 2018, 2018